Abstract
Large-scale projects integrating whole exome sequencing (WES), whole genome sequencing (WGS), and RNA sequencing (RNA-seq) have highlighted the new era of Cancer Precision Medicine. These studies have substantially expanded the cancer genes and targets catalogues. Moreover, intratumor heterogeneity and circulating cell-free DNA or tumor DNA (cfDNA, ctDNA) profiling with next generation sequencing are emerging as novel robust biomarkers to guide individualized meaningful treatment. In this review potential and challenges in the translation of these advances into cancer clinical care are discussed.

(Citation: Gastric & Breast Cancer 2022; 17(1): 34-40)

Back

PDF Version